Long-term Study of Flivas for BPH Identified Why Treatment Might Fail
News
A study exploring Flivas (naftopidil) in 117 patients with benign prostatic hyperplasia (BPH) demonstrates that long-term outcomes of the treatment vary widely. The report, “Three-year outcome analysis of alpha 1-blocker ... Read more